No takes yet. Share an insight, caveat, or question.
This research letter reveals CLAD phenotypes in lung transplant patients, suggesting improvements in management strategies.
Extract Chronic lung allograft dysfunction (CLAD) remains the primary cause of long-term death or graft-failure after lung transplantation. The ScanCLAD trial demonstrated that tacrolimus-based immunosuppression significantly reduced CLAD incidence compared to ciclosporin (13% versus 39% at 3 years). However, CLAD phenotyping was not part of the original protocol. We report the first comprehensive phenotype analysis from a prospective randomized controlled trial in lung transplantation, employing a structured consensus process to classify CLAD phenotypes and assess their stability over time.
Magnusson et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: